During National Apprenticeship Week apprentices and participating employers gathered at Oxford BioMedica to discuss how the first of its kind advanced therapies apprenticeship programme is key to meeting the industry demands for advanced therapies.
Dr Ian Campbell, interim Executive Chair, Innovate UK, delivered the keynote speech and highlighted the Government’s commitment to the programme. Other highlights of the day included a Q&A session with current apprentices and the launch of three new programmes in regulatory affairs, senior management and the Scottish modern apprenticeship in life sciences.
It's been 50 years since a new treatment for Parkinson's has been discovered. Current treatments focus on treating the motor symptoms of Parkinson's, and come with a whole host of often debilitating side effects. This video forms part of a BIA campaign called Celebrating UK Bioscience, and explores a project between BIA Charity of the year 2018, Parkinson's UK, and BIA member Benevolent AI. Harnessing the power of AI, they hope to identify new targets for drugs, and molecules which may have failed in their particular indication of study, but could be repurposed to help fight Parkinson's. Check out this video #WorldParkinsonsAwarenessWeek
With impeccable timing, we’ve got our next members’ Brexit webinar this Friday – the day of the next possible Brexit no-deal deadline. I expect that lots will change between now and then; we'll update you on what it all means for our sector. Wish us luck! The Conservative/Labour Brexit talks continue today, in the run up to the European Council on Wednesday. There, European leaders will discuss the Prime Minister’s request for an Article 50 extension to 30 June – which requires the agreement of all 27 EU members. At the same time the UK Parliament ‘taking back control’ continues, with Yvette Cooper’s European Union (Withdrawal) (No 5) Bill in the House of Lords today and returning to the House of Commons later this week.
The Fourth Industrial Revolution, which is characterised by a fusion of technologies and a blurring of the lines between the physical, digital, and biological spheres, is ushering in transformation across the life science industries.
Delivering the deal negotiated with the EU is the Government’s priority. However, preparing for any outcome is recommended and many UK-based pharmaceutical firms would be affected by a ‘No Deal’ Exit from the EU. Here are the top five tips on preparation for no-deal.
It’s now the second quarter of 2019 and frustratingly Brexit uncertainty continues. I don’t see it being resolved this week. I know many of you are, at high cost, making contingency plans for all eventualities. I am equally well aware of how the Westminster drama provides an unhelpful backdrop to those seeking global investment into UK businesses. This week, following the PM losing the vote on an amendment and another Withdrawal Agreement vote, Parliament will vote again on different Brexit options to see if there is a position that commands a majority of the House. The default in UK and EU law is that the UK will leave the EU on Friday week, 12 April 2019 without a deal, however avoiding a no-deal Brexit is the one thing for which there has been a majority in Parliament.
Imperial College School of Medicine is actively seeking industry placements for students in the third year of the innovative BSc Medical Biosciences (BMB) course. During this final year, students undertake specialist modules that specifically examine health problems in the 21st century, and elect a project in either a laboratory, literature-based research project or a work placement.
It was a pleasure to welcome up-and-coming life sciences entrepreneurs to The Crick for our PULSE programme – a 3 day workshop and networking event in partnership with the Crick designed to encourage innovative entrepreneurs to develop their life science business ideas last week.